INTRODUCTION AND OBJECTIVES:
Patients with urologic chronic pelvic pain syndromes (UCPPS, interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome) suffer pelvic pain and pain in other body areas. The distribution of this pain in the body and its association with other factors has not been systematically studied. We characterized the location and distribution of pain among men and women with a body map and compared urinary symptoms, non-urological factors, and psychosocial measures between UCPPS patients who reported 00 pelvic pain only, 00 00 pelvic pain and beyond, 00 and 00 widespread body pain.
00
METHODS: 233 women and 191 men with UCPPS enrolled in a multi-center, one-year observational study completed a battery of measures at study entry, including a body map to report the location and distribution of their pain during the past week. Participants were categorized as having 00 pelvic pain only 00 if they reported pain in the abdomen and pelvis only, or 00 pelvic pain and beyond 00 if they reported pain outside the abdomen and pelvis. Those who reported 00 pelvic pain and beyond 00 were sub-grouped into the numbers of broader body regions affected by pain (1-2 regions versus 3-7 regions or 00 widespread body pain 00 ). RESULTS: 25% reported pelvic pain only. 38% reported widespread body pain outside the abdomen and pelvis. As we moved from 0 region ( 00 pelvic pain only 00 ) to 1-2 regions to 3 body regions outside the abdomen/pelvis ( 00 widespread body pain 00 ), there is an increase in nonurologic pain (p<0.0001), more sleep disturbance (PROMIS, p¼0.035), worse quality of life (SF-12 physical component: p¼0.021; SF-12 mental component: p¼0.001), more depression (HADS-D, p¼0.005), higher anxiety (HADS-A, p¼0.011), higher psychological stress (PSS, p¼0.005), and higher negative affect scores (PANAS, p¼0.0004), using Jonchkheere 0 s trend test to test for 3-group gradient. Women (but not in men) with widespread pain also reported more fatigue (PROMIS, p<0.0001) than those with pelvic pain only. For both men and women, there was no difference between the three groups in terms of their urinary symptoms (e.g., severity of pelvic pain, urinary frequency, urgency ratings, Interstitial Cystitis Symptom and Problem Indexes, Genitourinary Pain Index, pain composite score, and urinary composite score).
CONCLUSIONS: Among MAPP participants, three out of four men and women with urologic chronic pelvic pain syndromes (UCPPS) also report pain outside the abdomen and pelvis. Widespread body pain was associated with worse quality of life and psychosocial impacts but not worse urinary symptoms. RESULTS: Stool results: In 55 of the 80 analysed women elevated histamine levels were found in fecal samples compared to a control-group of 57 healthy women.Moreover in most of the patients the protective anaerobic indicator microbiota (mainly lactobacilli and bifidobacteria) was also diminished. Vaginal swab results: In 39 out of the 55 women with the elevated histamine level the presence of Enterococcus ssp. and / or Enterobacteriaceae in vaginal swabs was also detected. In 12 women only the presence of Enterococcus ssp. and / or Enterobacteriaceae was found. 4 women did neither show elevated histamine levels nor the presence of histamine producing bacteria in vaginal swabs.
METHODS: Between
CONCLUSIONS: There are paralleles between IC and histamine intolerance: 1% of the population affected, 80% female and middle aged, symptom improvement in pregnancy because of a 500 fold higher level of the diamine oxidase (histamine eliminating enzyme). Histamine intolerance is a poorly described disease which can present with a variety of symptoms also found as comorbidities in IC patients like e.g. migraine, irritable bowel syndrome and urticaria. Histamine can increase intestinal permeability causing a leaky gut which prompts the body to initiate immune reactions causing autoimmune diseases and can also lead to pain through a toll-like receptor (TLR)-4 inflammatory response. That TLR-4 plays a role in pain has recently been demonstrated in IC patients by the MAPP research group. Moreover histamine alone as shown in mice can also cause pelvic pain.
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MP29-14 BLADDER CAPACITY IS A BIOMARKER FOR A BLADDER-CENTRIC VERSUS SYSTEMIC MANIFESTATION IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS)
Joao Zambon*, Steve J Walker, Gopal Badlani, Catherine Matthews, Heather Bowman, Robert Evans, Winston-Salem, NC INTRODUCTION AND OBJECTIVES: IC/BPS is a diagnosis of exclusion for which there is no specific cystoscopic or pathological marker. The symptom heterogeneity and the myriad comorbid medical conditions in this population add confusion to the clinical picture. We recently reported that a subset of IC/BPS patients with BC < 400 ml display a molecular profile that is consistent with an inflammatory disease phenotype. This study aims to correlate the bladder capacity (BC) measured by hydrodistension with urinary and gynecological symptoms, non-urological chronic diseases, cystoscopy & histopathology.
METHODS: This is a retrospective chart review of women diagnosed with IC/BPS between 2011 and 2015 at one tertiary referral institution (IRB#00018552) who underwent bladder hydrodistention per the AUA guideline algorithm. Assessments for each patient included history, physical examination, OLeary/Sant Voiding & Pain Indices (ICPI & ICSI), and the Pelvic Pain Urgency and Frequency Questionnaire (PUF). After hydrodistension, bladder biopsies were collected and analyzed for pathology. Inflammation severity was characterized according to the degree of submucosal lymphocyte and monocyte infiltration, basement membrane thickness, submucosal edema, vascular ectasia, and fibrosis.
RESULTS: This study, which included data from 145 consecutively consented IC/BPS patients found a significant inverse correlation between BC and scores on three gold standard IC/BPS metrics: ICPI (p¼0.0014), ICSI (p¼0.0022) and PUF (p¼0.0009), as well as with urinary frequency (p¼0.0025) and age (p¼0.014). A significant positive correlation was seen between BC and depression (p¼0.0059), and BC and IBS (p¼0.022). These data are demonstrated in Table 1 . Cystoscopy and hystopathology data are demonstrated in Graph 1. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e385
